



## Completion Of Entitlement Offer

**Emyria Limited (ASX: EMD)** ("**Emyria**" or the "**Company**") is pleased to announce the results of its non-renounceable pro rata entitlement offer to eligible shareholders (**Entitlement Offer**) announced on 4 September 2023, which closed on 28 September 2023.

The Entitlement Offer was made on the basis of 1 new fully paid ordinary share ("**New Share**") for every 7.5 existing shares held at the record date (13 September 2023) at an issue price of \$0.075 per New Share, plus 1 free attaching new option ("**New Option**") for every 2 New Shares subscribed for and issued.

The Company received valid applications from eligible shareholders totalling approximately \$1.18 million. The results of the Entitlement Offer are as follows:

|                                                         | SHARES     | OPTIONS    |
|---------------------------------------------------------|------------|------------|
| Maximum securities offered under the Offer <sup>1</sup> | 44,448,015 | 22,224,008 |
| Entitlement acceptances <sup>2</sup>                    | 15,709,711 | 7,854,778  |
| Shortfall securities to be placed                       | 28,738,304 | 14,369,230 |

It is anticipated that the New Shares and New Options for which valid applications have been received will be issued on 5 October 2023. The New Shares will rank equally with existing fully paid ordinary shares on issue. The New Options will have an exercise price of \$0.12 and an expiry date that is 3 years from the date of issue.

**Dr. Michael Winlo, CEO of Emyria**, commented: *"We are very pleased at the high level of support from our shareholders as reflected in the take-up of entitlements. We see this as a vote of confidence in our commitment to leading the evolution of mental health treatments highlighted by our focus on MDMA-assisted therapy and the Pax Centre acquisition. We're now moving to advance our MDMA-therapy roll-out and drug development initiatives. On behalf of the Board and Management, we thank our shareholders for backing our vision to transform mental health."*

### Shortfall

The directors and the Lead Manager, Sixty Two Capital Pty Ltd, reserve the right to place the Shortfall within 3 months of the closing date, subject to the requirements of the ASX Listing Rules and the *Corporations Act 2001* (Cth). The Company will update the market on the issue of any Shortfall in due course.

## RECENT TRACTION & UPCOMING MILESTONES

| CLINICAL DELIVERY                                     | THERAPY DEVELOPMENT              |                                                |
|-------------------------------------------------------|----------------------------------|------------------------------------------------|
| Advanced mental health care                           | MDMA-inspired Medicines          | Ultra-Pure Cannabinoids                        |
| Acquisition of leading psychological trauma service ✓ | First patent family filed ✓      | Preclinical Screening Program for Pain (RX7) ✓ |
| Commencement of MDMA-assisted therapy ✓               | US-focused preclinical program ✓ | Formulation optimisation (RX7 > RX9) ✓         |
| Expand treatment offerings ✓                          | Metabolic studies ✓              | AUS Commercial partner (RX5) ✓                 |
| Authorised Prescriber approvals                       | Preclinical animal models ✓      | US Commercial partners                         |
| Expansion of clinical footprint                       | Lead selection                   | Phase 3 conclusion (RX5)                       |
| Engagement with payers                                | Phase 1 trials                   | Phase 1 (RX7 & RX9)                            |
| Leverage data platform                                | Global commercial strategy       | FDA Pre-IND (RX7 & RX9)                        |

## NOTES

1. These numbers may vary due to rounding of entitlements and may increase as a result of the rounding up of New Shares and New Options offered under the Entitlement Offer.
2. Calculated based on entitlements taken up by eligible shareholders and additional subscriptions received from eligible shareholders above their entitlement.

This release has been approved by the Board of Emyria.

## FOR FURTHER INFORMATION

**Dr. Michael Winlo**  
**Managing Director**  
 +61 (0) 8 6559 2800  
[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Sara Polanski**  
**Communication Manager**  
 +61 (0) 404 110 099  
[media@emyria.com](mailto:media@emyria.com)

**Sufian Ahmad**  
**Corporate Advisor**  
 +61 (0) 412 316 162  
[info@62capital.com.au](mailto:info@62capital.com.au)

**Emyria Limited** is a clinical services and drug development company with a focus on revolutionising patient outcomes in neuroscience and mental health via:

generates

**Clinical Service Delivery:** With Emerald Clinics, and the recent acquisition of the Pax Centre, a leading psychological trauma center, Emyria delivers evidence-based and emerging therapies for mental health and other unmet needs.


informs

**Proprietary Real-World Data (RWD):** Through its advanced data platform powered by Palantir, Emyria collects robust and ethically-sourced Real-World Data to improve its care models and support its distinct therapy and drug development initiatives.

**Drug Discovery & Development:** Guided by its RWD, Emyria is developing several proprietary Ultra-Pure cannabinoid dose forms and advancing them towards registration. In parallel, we are establishing one of the world's largest libraries of MDMA-like compounds in partnership with the University of Western Australia.

## EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



paxcentre.com.au

**The Pax Centre** specialises in treating individuals grappling with the psychological impacts of traumatic experiences. Our treatment approach is highly personalised, addressing a wide range of mental health issues, from PTSD and depression to anxiety disorders and substance abuse, often stemming from various life traumas.

Complex trauma, characterised by repeated, relational traumatic events often occurring during developmental stages, requires specialised attention due to its pervasive and lasting impact. In these cases, The Pax Centre prioritises early diagnosis and evidence-based treatments.

We also focus on proactive strategies for health expansion and personal growth, empowering our clients with skills and tools to improve wellbeing and performance. At the Pax Centre, we believe in transforming lives through focused, evidence-based mental health care.



emeraldclinics.com.au

Emerald Clinics is an Australian-based, patient-centric clinical service specialising in providing treatments for patients with complex and chronic conditions, where traditional therapies might not have yielded satisfactory results.

Leveraging our deep expertise with unregistered medicines, such as cannabinoids, we strive to pioneer and personalise care for our patients. Our robust, ethically-sourced data collection methods underpin our commitment to improving patient outcomes and advancing healthcare innovation.

**CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS** Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.